◎ Sugi Atlas

Atlas / Gene / NEK5

NEK5

gene
On this page

Summary

NEK5 (NIMA related kinase 5, HGNC:7748) is a protein-coding gene on chromosome 13q14.3, encoding Serine/threonine-protein kinase Nek5 (Q6P3R8).

Predicted to enable protein kinase activity. Predicted to be involved in chromatin remodeling. Predicted to act upstream of or within positive regulation of striated muscle cell differentiation. Located in sperm flagellum.

Source: NCBI Gene 341676 — RefSeq curated summary.

At a glance

  • Clinical variants (ClinVar): 116 total
  • Druggable target: yes — 10 molecules with ChEMBL bioactivity
  • MANE Select transcript: NM_001365552

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:7748
Approved symbolNEK5
NameNIMA related kinase 5
Location13q14.3
Locus typegene with protein product
StatusApproved
Ensembl geneENSG00000197168
Ensembl biotypeprotein_coding
OMIM616731
Entrez341676

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 7 protein_coding, 1 nonsense_mediated_decay, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000355568, ENST00000465811, ENST00000529080, ENST00000617045, ENST00000647945, ENST00000652119, ENST00000652502, ENST00000684899, ENST00000966557, ENST00000966558

RefSeq mRNA: 2 — MANE Select: NM_001365552 NM_001365552, NM_199289

CCDS: CCDS31979, CCDS91811

Canonical transcript exons

ENST00000684899 — 24 exons

ExonStartEnd
ENSE000014008915208326052083352
ENSE000014017395210209252102292
ENSE000014028905210193352102014
ENSE000014035015209974352099876
ENSE000014214625210449852104552
ENSE000014234995211034052110410
ENSE000014247155210831852108404
ENSE000014261385211226852112365
ENSE000014267635211049452110577
ENSE000014294265211931952119415
ENSE000014303165207606352076143
ENSE000014324145209305452093235
ENSE000014763505212759552127662
ENSE000021884145212736652127504
ENSE000034930105208733852087454
ENSE000035795465207575852075826
ENSE000035866565207194452072070
ENSE000036067445208924752089313
ENSE000036173275208627752086363
ENSE000038324665206181952061953
ENSE000038332875205010452050221
ENSE000038338105206548452065609
ENSE000038381295203361152037218
ENSE000039320675212902952129073

Expression profiles

Bgee: expression breadth ubiquitous, 185 present calls, max score 98.32.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.2954 / max 24.8304, expressed in 141 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter IDTPM avgSamples expressed
1374100.2954141

Top tissues by expression

251 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
bronchial epithelial cellCL:000232898.32gold quality
bronchusUBERON:000218597.09gold quality
right uterine tubeUBERON:000130295.22gold quality
oviduct epitheliumUBERON:000480495.11gold quality
buccal mucosa cellCL:000233695.05gold quality
mucosa of paranasal sinusUBERON:000503095.05gold quality
endothelial cellCL:000011590.31gold quality
fallopian tubeUBERON:000388984.52gold quality
olfactory segment of nasal mucosaUBERON:000538684.22gold quality
spermCL:000001982.99gold quality
male germ line stem cell (sensu Vertebrata) in testisCL:0000089 ∩ UBERON:000047382.94gold quality
epithelium of nasopharynxUBERON:000195181.80gold quality
nasal cavity epitheliumUBERON:000538481.66gold quality
primordial germ cell in gonadCL:0000670 ∩ UBERON:000099179.47gold quality
caput epididymisUBERON:000435876.89gold quality
right testisUBERON:000453476.71gold quality
left testisUBERON:000453376.70gold quality
germinal epithelium of ovaryUBERON:000130476.42gold quality
testisUBERON:000047376.32gold quality
nasal cavity mucosaUBERON:000182671.56gold quality
ventricular zoneUBERON:000305370.58gold quality
calcaneal tendonUBERON:000370170.07gold quality
right lungUBERON:000216769.33gold quality
tendonUBERON:000004368.47gold quality
parietal pleuraUBERON:000240067.59gold quality
corpus callosumUBERON:000233667.21gold quality
hypothalamusUBERON:000189866.38gold quality
left uterine tubeUBERON:000130365.69gold quality
tendon of biceps brachiiUBERON:000818865.33silver quality
endometriumUBERON:000129564.48gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

ExperimentMarker?Max mean expression
E-CURD-114yes60.85
E-ANND-3yes9.68

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

25 targeting NEK5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNAMax scoreAvg scoremiRNA target_count
HSA-MIR-4713-3P100.0065.92505
HSA-MIR-4533100.0069.482758
HSA-MIR-196A-1-3P99.9972.152772
HSA-MIR-448799.9664.581252
HSA-MIR-6772-5P99.9467.01577
HSA-MIR-95-5P99.8972.173973
HSA-MIR-6764-5P99.7567.892304
HSA-MIR-494-3P99.7071.452795
HSA-MIR-320299.6667.702737
HSA-MIR-4690-5P99.6566.24813
HSA-MIR-1915-3P99.5866.791988
HSA-MIR-143-3P99.4969.051457
HSA-MIR-477099.4969.091451
HSA-MIR-608899.2968.451284
HSA-MIR-146A-3P99.1368.991881
HSA-MIR-5001-3P98.9167.281394
HSA-MIR-6760-5P98.8766.731515
HSA-MIR-19898.7067.32920
HSA-MIR-392197.8167.451431
HSA-MIR-144-5P97.6669.90531
HSA-MIR-4653-5P97.2267.721429
HSA-MIR-92197.0966.45562
HSA-MIR-3184-3P96.9666.91845
HSA-MIR-3156-5P96.9367.36800
HSA-MIR-3162-5P95.6767.53794

Literature-anchored findings (GeneRIF, showing 10)

  • The hNek5 is mitochondrial localization and its role on cell death and cell respiration defects through COX11, MTX2 and BCLAF1. (PMID:25725288)
  • Nek5 is required for the loss of centrosome linker proteins and enhanced microtubule nucleation that lead to timely centrosome separation and bipolar spindle formation in mitosis (PMID:25963817)
  • Data show that up-regulated NEK5 was significantly associated with breast tumor progression and poor overall prognosis; and that silencing of NEK5 can significantly suppress the proliferation both in vivo and in vitro, inhibiting migration, and invasion. NEK5 can up-regulate Cyclin A2 by direct interaction. (PMID:30675923)
  • NEK5 interacts with topoisomerase IIbeta and is involved in the DNA damage response induced by etoposide. (PMID:31090963)
  • the NEK protein kinases emerge as important proteins in thyroid cancer development and may help to identify malignancy and aggressiveness features during diagnosis. (PMID:31906878)
  • Knockdown of lncRNA XIST inhibits hypoxia-induced glycolysis, migration and invasion through regulating miR-381-3p/NEK5 axis in nasopharyngeal carcinoma. (PMID:32196601)
  • NEK5 interacts with LonP1 and its kinase activity is essential for the regulation of mitochondrial functions and mtDNA maintenance. (PMID:33547867)
  • Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review. (PMID:33749548)
  • NEK5 activity regulates the mesenchymal and migratory phenotype in breast cancer cells. (PMID:34196902)
  • Identification of biological pathways and processes regulated by NEK5 in breast epithelial cells via an integrated proteomic approach. (PMID:36550548)

Cross-species orthologs

2 orthologs

OrganismSymbolGene ID
mus_musculusNek5ENSMUSG00000037738
rattus_norvegicusNek5ENSRNOG00000048769

Paralogs (8): NEK11 (ENSG00000114670), NEK2 (ENSG00000117650), NEK6 (ENSG00000119408), NEK9 (ENSG00000119638), NEK3 (ENSG00000136098), NEK7 (ENSG00000151414), NEK8 (ENSG00000160602), NEK10 (ENSG00000163491)

Protein

Protein identifiers

Serine/threonine-protein kinase Nek5 — Q6P3R8 (reviewed: Q6P3R8)

Alternative names: Never in mitosis A-related kinase 5

All UniProt accessions (5): A0A3B3ITQ6, A0A494C168, A0A8I5KQI9, E9PIX7, Q6P3R8

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Cell projection. Cilium. Flagellum.

Similarity. Belongs to the protein kinase superfamily. NEK Ser/Thr protein kinase family. NIMA subfamily.

RefSeq proteins (2): NP_001352481, NP_954983 (=MANE)

Domains & families (InterPro)

IDNameType
IPR000719Prot_kinase_domDomain
IPR008271Ser/Thr_kinase_ASActive_site
IPR011009Kinase-like_dom_sfHomologous_superfamily
IPR017441Protein_kinase_ATP_BSBinding_site
IPR051131NEK_Ser/Thr_kinase_NIMAFamily

Pfam: PF00069

Catalyzed reactions (Rhea), 2 shown:

  • L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
  • L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (11 total): sequence variant 3, region of interest 2, binding site 2, chain 1, domain 1, compositionally biased region 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-Q6P3R8-F159.660.26

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 128 (proton acceptor)

Ligand- & substrate-binding residues (2): 10–18; 33

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 43 (showing top): SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN, chr13q14, GOCC_MOTILE_CILIUM, GOCC_CILIUM, GOMF_PROTEIN_KINASE_ACTIVITY, GOMF_KINASE_ACTIVITY, GOMF_PROTEIN_SERINE_THREONINE_KINASE_ACTIVITY, DODD_NASOPHARYNGEAL_CARCINOMA_DN, GOMF_ADENYL_NUCLEOTIDE_BINDING, GOMF_TRANSFERASE_ACTIVITY_TRANSFERRING_PHOSPHORUS_CONTAINING_GROUPS, GOCC_9PLUS2_MOTILE_CILIUM, CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_UP, GSE5503_MLN_DC_VS_PLN_DC_ACTIVATED_ALLOGENIC_TCELL_DN, GSE13522_WT_VS_IFNG_KO_SKIN_UP, ZNF7_TARGET_GENES

GO Biological Process (2): protein phosphorylation (GO:0006468), positive regulation of striated muscle cell differentiation (GO:0051155)

GO Molecular Function (8): protein kinase activity (GO:0004672), protein serine/threonine kinase activity (GO:0004674), ATP binding (GO:0005524), metal ion binding (GO:0046872), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (4): cilium (GO:0005929), sperm flagellum (GO:0036126), motile cilium (GO:0031514), cell projection (GO:0042995)

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
protein kinase activity2
phosphorylation1
protein modification process1
striated muscle cell differentiation1
positive regulation of muscle cell differentiation1
regulation of striated muscle cell differentiation1
kinase activity1
phosphotransferase activity, alcohol group as acceptor1
catalytic activity, acting on a protein1
adenyl ribonucleotide binding1
purine ribonucleoside triphosphate binding1
cation binding1
nucleoside phosphate binding1
heterocyclic compound binding1
transferase activity, transferring phosphorus-containing groups1
catalytic activity1
intraciliary transport particle1
membrane-bounded organelle1
plasma membrane bounded cell projection1
9+2 motile cilium1
cilium1
cellular anatomical structure1

Protein interactions and networks

STRING

632 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
NEK5COX11Q9Y6N1507
NEK5BCLAF1Q9NYF8490
NEK5TMEM69Q5SWH9394
NEK5CLPPQ16740375
NEK5CCDC137Q6PK04339
NEK5LRRC45Q96CN5333
NEK5ADGRG2Q8IZP9333
NEK5CROCCQ5TZA2332
NEK5HIPK4Q8NE63325
NEK5CSRNP2Q9H175319
NEK5ANKRD34BA5PLL1317
NEK5NAGKQ9UJ70315
NEK5C1QTNF7Q9BXJ2311
NEK5MRGPRX3Q96LB0309
NEK5FN3KQ9H479306

IntAct

6 interactions, top by confidence:

ABTypeScore
NEK1CFAP410psi-mi:“MI:0914”(association)0.510
Ppsi-mi:“MI:0914”(association)0.350
Mpsi-mi:“MI:0914”(association)0.350
FTLSH3PXD2Bpsi-mi:“MI:0914”(association)0.350
NEK5NEK1psi-mi:“MI:0915”(physical association)0.000

BioGRID (10): NEK1 (Affinity Capture-MS), NEK5 (Synthetic Lethality), NEK5 (Affinity Capture-MS), NEK5 (Affinity Capture-MS), NEK5 (Affinity Capture-MS), NEK5 (Positive Genetic), HMGB1 (Cross-Linking-MS (XL-MS)), ATP5B (Cross-Linking-MS (XL-MS)), NEK5 (Cross-Linking-MS (XL-MS)), RPL26 (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0AUV4, A0JM98, A1A5Q6, A2KF29, B1WAS2, C0HKC8, C0HKC9, O60285, O70551, O88866, P51957, P57058, P57059, Q2T9U5, Q4R9F7, Q5R7G9, Q5RD27, Q5REX1, Q5XHI9, Q60670, Q641K5, Q66HE5, Q68UT7, Q6IFT4, Q6P3R8, Q6REY9, Q6VZ17, Q80VH0, Q8BI55, Q8BLD6, Q8BZN4, Q8C0N0, Q8C0V7, Q8C0X8, Q8CFH6, Q8NE63, Q8TF76, Q96SB4, Q9H093, Q9H0K1

Diamond homologs: A0A078CGE6, A2BD05, A2QHV0, A2ZMH2, A7SNN5, D3ZBE5, D3ZGQ5, E9Q3S4, G5EFM9, H2L099, O01775, O13839, O14047, O22040, O22042, O35942, O61122, P11837, P22209, P41892, P48479, P48963, P51954, P51955, P51956, P51957, P59895, P84199, Q03428, Q08942, Q0CL79, Q0KHQ5, Q0WPH8, Q10GB1, Q2QAV0, Q2QMH1, Q3SWY6, Q3UGM2, Q40541, Q4FZD7

SIGNOR signaling

1 interactions.

AEffectBMechanism
NEK5“up-regulates activity”CCNA2binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

116 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic0
Likely pathogenic0
Uncertain significance95
Likely benign9
Benign0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3691 predictions. Top by Δscore:

VariantEffectΔscore
13:52072113:T:TCacceptor_gain1.0000
13:52076057:TCTTA:Tdonor_loss1.0000
13:52076058:CTTAC:Cdonor_loss1.0000
13:52076059:TTA:Tdonor_loss1.0000
13:52076060:TA:Tdonor_loss1.0000
13:52076061:ACC:Adonor_loss1.0000
13:52076062:C:CAdonor_loss1.0000
13:52076140:TGTC:Tacceptor_gain1.0000
13:52086270:AATTT:Adonor_loss1.0000
13:52086271:ATTT:Adonor_loss1.0000
13:52086272:TTTAC:Tdonor_loss1.0000
13:52086273:TTA:Tdonor_loss1.0000
13:52086274:TACC:Tdonor_loss1.0000
13:52086275:ACCTC:Adonor_loss1.0000
13:52086276:C:CTdonor_loss1.0000
13:52086276:CCT:Cdonor_gain1.0000
13:52087342:T:TAdonor_gain1.0000
13:52089315:T:Cacceptor_gain1.0000
13:52089315:T:TCacceptor_gain1.0000
13:52127359:A:Cdonor_gain1.0000
13:52127360:CTTTA:Cdonor_loss1.0000
13:52127361:TTTA:Tdonor_loss1.0000
13:52127362:TTAC:Tdonor_loss1.0000
13:52127363:TACC:Tdonor_loss1.0000
13:52127364:ACCT:Adonor_loss1.0000
13:52127501:TTTC:Tacceptor_gain1.0000
13:52127503:TC:Tacceptor_gain1.0000
13:52127504:CC:Cacceptor_gain1.0000
13:52127505:C:CCacceptor_gain1.0000
13:52127506:T:Cacceptor_loss1.0000

AlphaMissense

5572 scored. Top likely-pathogenic:

VariantProtein changeam_pathogenicity
13:52110507:T:AD128V0.998
13:52110507:T:GD128A0.998
13:52127384:T:AK33N0.998
13:52127384:T:GK33N0.998
13:52104545:A:GW188R0.997
13:52104545:A:TW188R0.997
13:52110500:T:AK130N0.996
13:52110500:T:GK130N0.996
13:52110501:T:AK130I0.996
13:52110543:A:GL116P0.996
13:52104517:A:GL197P0.995
13:52110366:G:CD147E0.995
13:52110366:G:TD147E0.995
13:52110367:T:AD147V0.995
13:52110506:G:CD128E0.995
13:52110506:G:TD128E0.995
13:52110507:T:CD128G0.995
13:52104551:C:GD186H0.994
13:52110367:T:GD147A0.994
13:52110568:A:GW108R0.994
13:52110568:A:TW108R0.994
13:52112331:A:CC83W0.994
13:52102290:A:CF204L0.993
13:52102290:A:TF204L0.993
13:52102292:A:GF204L0.993
13:52104543:C:AW188C0.993
13:52104543:C:GW188C0.993
13:52110367:T:CD147G0.993
13:52110368:C:GD147H0.993
13:52127385:T:AK33I0.993

dbSNP variants (sampled 300 via entrez): RS1000018567 (13:52129714 A>T), RS1000034579 (13:52041379 G>A), RS1000059191 (13:52082247 G>A,C,T), RS1000076538 (13:52129617 A>C), RS1000104736 (13:52094611 G>A), RS1000132909 (13:52034831 GCCA>G), RS1000186218 (13:52073474 C>T), RS1000187552 (13:52056025 C>A), RS1000229644 (13:52068041 G>A), RS1000237926 (13:52067850 C>A,T), RS1000248660 (13:52063327 G>A), RS1000267439 (13:52109099 C>T), RS1000274331 (13:52116495 T>C), RS1000312272 (13:52095599 G>C), RS1000315772 (13:52050172 C>T)

Disease associations

OMIM: gene MIM:616731 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL4524130 (PROTEIN FAMILY), CHEMBL5044 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

10 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 32,685 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

MoleculeNamePhasePatents
CHEMBL1287853FEDRATINIB43,554
CHEMBL477772PAZOPANIB415,540
CHEMBL522892DOVITINIB34,944
CHEMBL603469LESTAURTINIB3
CHEMBL475251R-4062762
CHEMBL558752RAF-26522,721
CHEMBL572878TOZASERTIB22,998
CHEMBL1908394GSK-46136411,093
CHEMBL1908397KW-24491622
CHEMBL574738AST-4871451

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — NIMA (never in mitosis gene a)- related kinase (NEK) family

Binding affinities (BindingDB)

5 measured of 5 human assays (5 total across all organisms); most potent 5 below. Values come from heterogeneous assays and are not directly comparable.

LigandMeasureValue
StaurosporineKD1.7 nM
(3Z)-4-amino-5-fluoro-3-[5-(4-methylpiperazino)-1,3-dihydrobenzimidazol-2-ylidene]carbostyrilKD520 nM
N-[4-({4-[(3-methyl-1H-pyrazol-5-yl)amino]-6-(4-methylpiperazin-1-yl)pyrimidin-2-yl}sulfanyl)phenyl]cyclopropanecarboxamideKD1100 nM
1-[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]ureaKD1400 nM
1-methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amineKD4500 nM

ChEMBL bioactivities

32 potent at pChembl≥5 of 32 total, top 22 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChemblTypeValueUnitMolecule
7.89Kd13nMR-406
7.12IC5076.3nMSTAUROSPORINE
7.11IC5077.4nMSTAUROSPORINE
7.01IC5096.5nMSTAUROSPORINE
6.88IC50132nMCHEMBL5575113
6.24Kd570nMFEDRATINIB
6.14Kd730nMCHEMBL537757
6.09Kd810nMSTAUROSPORINE
6.05Kd890nMCHEMBL386051
6.00IC501000nMTP-030-1
6.00IC501000nMTP-030-2
6.00IC501000nMTP-030n
5.96Kd1100nMAST-487
5.96Kd1100nMGSK-461364
5.85Kd1400nMCHEMBL2425628
5.64Kd2300nMKW-2449
5.64Kd2300nMDOVITINIB
5.50Kd3200nMRAF-265
5.38Kd4200nMTOZASERTIB
5.36IC504420nMCHEMBL3745885
5.25Kd5600nMLESTAURTINIB
5.14Kd7300nMPAZOPANIB

PubChem BioAssay actives

29 with measured affinity, of 252 total; 16 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

CompoundAssayTypeValueUnit
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one1948826: Inhibition of NEK5 (unknown origin) assessed as dissociation constantkd0.0130uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one1715241: Inhibition of human NEK5 using MBP as substrate by [gamma-33P]-ATP assayic500.0763uM
N-propan-2-yl-4-[[4-(2-pyrrolidin-1-ylquinazolin-6-yl)pyrimidin-2-yl]amino]benzamide2095013: Inhibition of NEK5 (unknown origin) in presence of ATPic500.1320uM
Fedratinib1948826: Inhibition of NEK5 (unknown origin) assessed as dissociation constantkd0.5700uM
7-(1H-indol-2-yl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine1948826: Inhibition of NEK5 (unknown origin) assessed as dissociation constantkd0.7300uM
6-(2,6-dichlorophenyl)-8-methyl-2-(3-methylsulfanylanilino)pyrido[2,3-d]pyrimidin-7-one1948826: Inhibition of NEK5 (unknown origin) assessed as dissociation constantkd0.8900uM
1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]urea1948826: Inhibition of NEK5 (unknown origin) assessed as dissociation constantkd1.1000uM
5-[6-[(4-methylpiperazin-1-yl)methyl]benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxamide624742: Binding constant for NEK5 kinase domainkd1.1000uM
(4-hydroxypiperidin-1-yl)-[4-[[4-[4-(3-methylsulfonylpropoxy)indol-1-yl]pyrimidin-2-yl]amino]cyclohexyl]methanone769501: Binding affinity to NEK5 (unknown origin)kd1.4000uM
[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone1948826: Inhibition of NEK5 (unknown origin) assessed as dissociation constantkd2.3000uM
4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one435534: Binding constant for NEK5 kinase domainkd2.3000uM
1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine435534: Binding constant for NEK5 kinase domainkd3.2000uM
N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide435534: Binding constant for NEK5 kinase domainkd4.2000uM
6-(2,4-difluorophenyl)sulfonyl-2-(1H-indol-5-ylamino)-8-methylpyrido[2,3-d]pyrimidin-7-one1269895: Inhibition of human NEK5 using MBP as substrateic504.4200uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one624742: Binding constant for NEK5 kinase domainkd5.6000uM
Pazopanib624742: Binding constant for NEK5 kinase domainkd7.3000uM

CTD chemical–gene interactions

12 total (human), top 12 by PubMed support.

ChemicalActions (top 5)PubMed papers
benzo(e)pyreneincreases methylation1
aflatoxin B2increases methylation1
Sunitinibincreases expression1
Fulvestrantincreases methylation1
Air Pollutantsincreases abundance, increases expression1
Benzo(a)pyrenedecreases methylation, increases methylation1
Methapyrileneincreases methylation1
Smokeincreases expression, increases abundance1
Tobacco Smoke Pollutiondecreases expression1
Tretinoindecreases expression1
Triclosanincreases expression1
Aflatoxin B1increases methylation1

ChEMBL screening assays

96 unique, capped per target: 96 binding

Representative assays (with source publication via chembl_document):

Assay IDTypeDescriptionSource paper
CHEMBL4887137BindingNEK Invitrogen kinase activity assayData for DCP probe PF-04554878

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 79

This page pulls from 79 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgtopdb_interactiongwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomerefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot